Associated Papers
The role of zongertinib, a highly selective tyrosine kinase inhibitor, in targeting HER2-mutant NSCLC: a bench-to-bedside review.
Heymach JV et al.
Expert Review of Anticancer Therapy, 2026
Genomic Profile of Non-Small Cell Lung Cancer in a Spanish Cohort: A 2-Year Descriptive Study Using Next-Generation Sequencing.
Carnero-Gregorio M et al.
Genes, 2026
Hotspot mutations in HER2 interfaces destabilize structure, causing breast cancer treatment failure.
Dey P et al.
Oncogene, 2026
Integrating evidence from protein domains to identify cancer driver mutations.
Ostroverkhova D et al.
Protein Science : a Publication of the Protein Society, 2026
Concurrent genomic assessment of circulating tumour cells and ctDNA to guide therapy in metastatic breast cancer.
Allsopp RC et al.
Bmc Cancer, 2025
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
Diagnostic utility of ESR1 mutation detection in liquid biopsy of metastatic breast cancer patients.
Sandbothe M et al.
Virchows Archiv : an International Journal of Pathology, 2025
HER2 alterations across solid tumors: implications for comprehensive testing.
Ismail A et al.
The Oncologist, 2025
Profiling of HER2, KRAS, and PIK3CA mutations in uterine cervical neuroendocrine carcinoma and implications for oncogenic driver targeting therapy.
Chao WR et al.
Cancer Genetics, 2025
MutationAssessor in cBioPortal.
Su Y et al.
Biorxiv : the Preprint Server for Biology, 2025
Mutational Landscape Assessed in Tumor Tissue and Circulating Tumor DNA During Treatment of Patients with HER2/ERBB2-Mutated Solid Tumors.
Egebjerg K et al.
Bmc Cancer, 2025
Comprehensive cross-sectional study of CIN prevalence, HPV genotyping, genetic alterations, and microbiota as molecular biomarkers for early cervical cancer detection: A pilot clinical study among women in Russia.
Romanishin A et al.
International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics, 2025
[Characteristics of KRAS and HER-family gene mutations in ampullary cancer].
Zeng LL et al.
Zhonghua Bing Li Xue Za Zhi = Chinese Journal of Pathology, 2025
Circulating tumor DNA profiling for non-invasive genomic analysis in Indian lung cancer patients: A real-world experience.
Jha P et al.
The Journal of Liquid Biopsy, 2025
Selective targeting of oncogenic hotspot mutations of the HER2 extracellular domain.
Bang I et al.
Nature Chemical Biology, 2025
Clinical Validation of a Targeted RNA-Sequencing Assay for Driver Gene Alteration Detection in Non-Small Cell Lung Cancer.
Li J et al.
Molecular Diagnosis & Therapy, 2025
Frequency of targetable genetic alterations in resectable lung adenocarcinoma: Results from the LORD project.
Bossé Y et al.
Lung Cancer (amsterdam, Netherlands), 2025
Molecular profile of micropapillary urothelial carcinoma of the urinary bladder: An analysis of 99 cases by next-generation sequencing.
Shen Y et al.
Human Pathology, 2025
Revisiting variation in the somatic mutation landscape of non-small cell lung cancer.
Pathak V et al.
Hgg Advances, 2025
Plasmacytoid urothelial carcinoma of the urinary bladder: A single institution experience with focus on next-generation sequencing (NGS) and PD-L1 immunohistochemistry.
Korentzelos D et al.
Human Pathology, 2025
Hotspot mutations in HER2 interfaces destabilize structure, causing breast cancer treatment failure.
De A et al.
Research Square, 2025
Multi-gene panel sequencing reveals the relationship between driver gene mutation and clinical characteristics in lung adenocarcinoma.
Li J et al.
Discover Oncology, 2025
First-Line Pyrotinib Combination Therapy for HER2-Mutated Advanced NSCLC: A Retrospective Cohort Analysis.
Xiang Y et al.
Current Oncology (toronto, Ont.), 2025
Single-center analysis of a real-world cohort of patients with metastatic urothelial carcinoma evaluated by NGS: molecular landscape and efficacy of targeted therapies.
Gutiérrez Pérez C et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2025
DNA damage response and repair gene mutations predict clinical outcomes in biliary tract cancer.
Tan S et al.
Cancer, 2025
Utilizing Patient-Derived Xenografts to Model Precision Oncology for Biliary Tract Cancer.
DiPeri TP et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
Computational-aided rational mutation design of pertuzumab to overcome active HER2 mutation S310F through antibody-drug conjugates.
Bai X et al.
Proceedings of the National Academy of Sciences of the United States of America, 2025
Decoding the molecular landscape: HER2 and PD-L1 in advanced gastric cancer.
Yao J et al.
Frontiers in Immunology, 2025
The mutational landscape and actionable targets of gallbladder cancer: an ancestry-informed and comparative analysis of a Chilean population.
Erices JI et al.
Frontiers in Oncology, 2025
The theory of massively repeated evolution and full identifications of cancer-driving nucleotides (CDNs).
Zhang L et al.
Elife, 2024
Real-World Prevalence, Treatment Patterns, and Outcomes for Patients With HER2 (ERBB2)-Mutant Metastatic Non-Small Cell Lung Cancer, From a US-Based Clinico-Genomic Database.
Waliany S et al.
Cancer Medicine, 2024
PD-L1 and nectin-4 expression and genomic characterization of bladder cancer with divergent differentiation.
Martini DJ et al.
Cancer, 2024
Plasma-based analysis of ERBB2 mutational status by multiplex digital PCR in a large series of patients with metastatic breast cancer.
Corné J et al.
Molecular Oncology, 2024
Molecular landscape of ERBB2 alterations in 3000 advanced NSCLC patients.
Hong L et al.
Npj Precision Oncology, 2024
HER2 mutations in advanced cervical neuroendocrine carcinoma: implications for trastuzumab deruxtecan therapy.
Chao WR et al.
Naunyn-schmiedeberg's Archives of Pharmacology, 2024
ERBB2 mutations define a subgroup of endometrial carcinomas associated with high tumor mutational burden and the microsatellite instability-high (MSI-H) molecular subtype.
Brodeur MN et al.
Molecular Oncology, 2024
Optimal systemic treatment and real-world clinical application of ctDNA in patients with metastatic HER2-mutant lung cancer.
Liu SY et al.
European Journal of Cancer (oxford, England : 1990), 2024
Clinical and Genomic Characterization of ERBB2-Altered Gallbladder Cancer: Exploring Differences Between an American and a Chilean Cohort.
Mondaca S et al.
Jco Global Oncology, 2024
A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutation.
Thavaneswaran S et al.
Npj Precision Oncology, 2024
Clinical and structural insights into the rare but oncogenic HER2-activating missense mutations in non-small cell lung cancer: a retrospective ATLAS cohort study.
Yang G et al.
Discover Oncology, 2024